Exact Therapeutics As Stock Five Year Return
| EXTX Stock | NOK 3.58 0.18 5.29% |
Exact Therapeutics AS fundamentals help investors to digest information that contributes to Exact Therapeutics' financial success or failures. It also enables traders to predict the movement of Exact Stock. The fundamental analysis module provides a way to measure Exact Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exact Therapeutics stock.
Exact |
Exact Therapeutics AS Company Five Year Return Analysis
Exact Therapeutics' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, Exact Therapeutics AS has a Five Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Norway stocks average (which is currently at 0.0).
Exact Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exact Therapeutics' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exact Therapeutics could also be used in its relative valuation, which is a method of valuing Exact Therapeutics by comparing valuation metrics of similar companies.Exact Therapeutics is currently under evaluation in five year return category among its peers.
Exact Fundamentals
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (844.98) % | |||
| Current Valuation | 432.68 M | |||
| Shares Outstanding | 30 M | |||
| Shares Owned By Insiders | 64.13 % | |||
| Shares Owned By Institutions | 26.24 % | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 8,803 X | |||
| Gross Profit | 52 K | |||
| EBITDA | (56.66 M) | |||
| Net Income | (58.59 M) | |||
| Current Ratio | 15.66 X | |||
| Book Value Per Share | 2.60 X | |||
| Cash Flow From Operations | (55.11 M) | |||
| Earnings Per Share | (1.95) X | |||
| Beta | 0.21 | |||
| Market Capitalization | 359.97 M | |||
| Total Asset | 117.63 M | |||
| Net Asset | 117.63 M |
About Exact Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exact Therapeutics AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exact Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exact Therapeutics AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.